Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 3/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14046931 | 1.00 | F12 (0.40) | F12PDE10AP2RX3NR1H2PARP1 | |
| SCHEMBL13329427 | 0.89 | F12 (0.38) | F12PDE10AP2RX3NR1H2PARP1 | |
| SCHEMBL13329667 | 0.88 | PRLHR (0.40) | F12PDE10AP2RX3NR1H2PARP1 | |
| SCHEMBL13328851 | 0.87 | F12 (0.43) | F12PDE10AP2RX3NR1H2PARP1 | |
| SCHEMBL13250299 | 0.84 | PARP1 (0.42) | F12P2RX3NR1H2PARP1TNKS2 | |
| SCHEMBL13250124 | 0.82 | P2RX3 (0.46) | F12P2RX3NR1H2PARP1TNKS2 | |
| SCHEMBL13250311 | 0.82 | PARP1 (0.41) | F12P2RX3NR1H2PARP1TNKS2 | |
| SCHEMBL13250394 | 0.82 | PARP1 (0.43) | F12P2RX3NR1H2PARP1TNKS2 | |
| SCHEMBL13329462 | 0.82 | F12 (0.39) | F12PDE10AP2RX3NR1H2PARP1 | |
| SCHEMBL13250373 | 0.81 | PARP1 (0.42) | F12P2RX3NR1H2PARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR17 | F12 4881/4885PDE10A 1348/4885P2RX3 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.